1. Scrip
  2. >>Therapy Areas
  3. >>Cardiovascular

AZ’s Farxiga Gets FDA Priority Review For Heart Failure

Moves Ahead of Rival SGLT2 Inhibitors

 
• By Kevin Grogan

AstraZeneca has got off to a strong start in 2020, with the FDA granting a fast review for its diabetes drug Farxiga in heart failure and China approving Lokelma for hyperkalemia.

Priority_Fast_Lane
FDA not keeping AstraZeneca waiting • Source: Shutterstock

Having ended 2019 with two new approvals from the US Food and Drug Administration, AstraZeneca PLC is getting a speedy evaluation by the agency for a label expansion on Farxiga which will boost its leadership over other SGLT2 inhibitor diabetes drugs in the treatment of heart failure (HF).

The FDA has granted a priority review for Farxiga (dapagliflozin) to reduce the risk of cardiovascular death or the worsening of HF in adults with reduced ejection fraction (HFrEF) with and without type 2 diabetes

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Cardiovascular

More from Therapy Areas

Verastem Wins Approval For Novel Drug Combo In Rare Ovarian Cancer

 
• By Jessica Merrill

The novel RAF/MEK inhibitor and FAK inhibitor are the first treatment approved specifically for KRAS-mutated recurrent low-grade serious ovarian cancer (LGSOC).

CRISPR Therapeutics Unveils Promising Early In Vivo Cholesterol-Lowering Results

 
• By Andrew McConaghie

The Phase I results are the best to date among ANGPTL3-targeting candidates in the pipeline, but analysts will wait for further updates before predicting a likely winner.

Shionogi In $1bn Deal For Japan Tobacco’s Pharma Ops

 
• By Ian Haydock

Mid-sized Japanese pharma firm to acquire tobacco giant’s pharma operations and take private the listed Torii Pharmaceutical business, in bid to build sales reach and strengthen manufacturing.